Chemoprevention of hepatocellular carcinoma associated with metabolic dysfunction-associated steatotic liver disease: an updated review

Abstract

With the predicted rise in metabolic dysfunction-associated steatotic liver disease (MASLD) prevalence over the next decade, strategies to prevent hepatocellular carcinoma (HCC), which is the third most common cause of cancer-related death, are paramount. In this narrative review, we present recent clinical and translational studies from 2020-2024, providing an updated overview of the literature on chemoprevention of HCC associated with MASLD. We specifically focus on statins, aspirin, metformin, and newer diabetes medications. These agents target specific steps in the development of HCC in MASLD, including steatosis resulting in oxidative stress, inflammation, and eventually fibrosis. All offer promising avenues for HCC chemoprevention, although statins have the strongest data at present. Further ongoing prospective studies are needed.

Keywords

MASLD / statins / aspirin / semaglutide / liver-related events

References

[1] Rumgay H,de Martel C.Global, regional and national burden of primary liver cancer by subtype.Eur J Cancer2022;161:108-18

[2] Chidambaranathan-Reghupaty S,Sarkar D.Hepatocellular carcinoma (HCC): epidemiology, etiology and molecular classification.Adv Cancer Res2021;149:1-61 PMCID:PMC8796122

[3] Miao L,Byrne CD,Zheng MH.Current status and future trends of the global burden of MASLD.Trends Endocrinol Metab2024;35:697-707

[4] Younossi ZM.Non-alcoholic fatty liver disease - a global public health perspective.J Hepatol2019;70:531-44

[5] Younossi ZM,Paik JM,Van Dongen C.The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.Hepatology2023;77:1335-47 PMCID:PMC10026948

[6] Estes C,Loomba R,Sanyal AJ.Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.Hepatology2018;67:123-33 PMCID:PMC5767767

[7] Bessone F,Roma MG.Molecular pathways of nonalcoholic fatty liver disease development and progression.Cell Mol Life Sci2019;76:99-128 PMCID:PMC11105781

[8] Ascha MS,Lopez R,Feldstein AF.The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis.Hepatology2010;51:1972-8

[9] Fang YL,Wang CL.Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: from “two hit theory” to “multiple hit model”.World J Gastroenterol2018;24:2974-83 PMCID:PMC6054950

[10] Peiseler M,Hampe J,Heikenwälder M.Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits.J Hepatol2022;77:1136-60

[11] Nelson NP,McMahon BJ.Epidemiology of hepatitis B virus infection and impact of vaccination on disease.Clin Liver Dis2016;20:607-28 PMCID:PMC5582972

[12] Leong TY.Epidemiology and carcinogenesis of hepatocellular carcinoma.HPB2005;7:5-15 PMCID:PMC2023917

[13] Hurwitz LM,Jordan SJ.Modification of the association between frequent aspirin use and ovarian cancer risk: a meta-analysis using individual-level data from two ovarian cancer consortia.J Clin Oncol2022;40:4207-17 PMCID:PMC9916035

[14] Shah D,Toh JWT.Aspirin chemoprevention in colorectal cancer: network meta-analysis of low, moderate, and high doses.Br J Surg2023;110:1691-702

[15] Iannacone M,Isogawa M.Platelets mediate cytotoxic T lymphocyte-induced liver damage.Nat Med2005;11:1167-9 PMCID:PMC2908083

[16] Simon TG,Osganian S.Daily aspirin use associated with reduced risk for fibrosis progression in patients with nonalcoholic fatty liver disease.Clin Gastroenterol Hepatol2019;17:2776-84.e4 PMCID:PMC6842070

[17] Koga H,Ohishi M.Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation.Hepatology1999;29:688-96

[18] Chen H,Chu ESH.Hepatic cyclooxygenase-2 overexpression induced spontaneous hepatocellular carcinoma formation in mice.Oncogene2017;36:4415-26 PMCID:PMC5543258

[19] Tang TC,Lau CP,Fan ST.Tumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma.World J Gastroenterol2005;11:1896-902 PMCID:PMC4305708

[20] Lu SC,Tan JT.Association between COX-2 gene polymorphisms and risk of hepatocellular carcinoma development: a meta-analysis.BMJ Open2015;5:e008263 PMCID:PMC4606424

[21] Wang S,Lin Z,Chen R.The relationship between aspirin consumption and hepatocellular carcinoma: a systematic review and meta-analysis.Eur J Med Res2023;28:226 PMCID:PMC10329378

[22] Yan LJ,Li HC.Efficacy and safety of aspirin for prevention of hepatocellular carcinoma: an updated meta-analysis.J Clin Transl Hepatol2022;10:835-46 PMCID:PMC9547262

[23] Tan RZH,Abdel Shaheed C.Systematic review with meta-analysis: the effects of non-steroidal anti-inflammatory drugs and anti-platelet therapy on the incidence and recurrence of hepatocellular carcinoma.Aliment Pharmacol Ther2021;54:356-67

[24] Simon TG,Stoyanova S.Aspirin for metabolic dysfunction-associated steatotic liver disease without cirrhosis: a randomized clinical trial.JAMA2024;331:920-9 PMCID:PMC10951738

[25] Ma S,Sun C.Does aspirin reduce the incidence, recurrence, and mortality of hepatocellular carcinoma? A GRADE-assessed systematic review and dose-response meta-analysis.Eur J Clin Pharmacol2023;79:39-61

[26] Chan AT.Aspirin, non-steroidal anti-inflammatory drugs and colorectal neoplasia: future challenges in chemoprevention.Cancer Causes Control2003;14:413-8

[27] Zhou X,Sun Y.Systematic review and meta-analysis: association of aspirin with incidence of hepatocellular carcinoma.Front Pharmacol2022;13:764854 PMCID:PMC8921872

[28] Goh MJ.Statin and aspirin for chemoprevention of hepatocellular carcinoma: time to use or wait further?.Clin Mol Hepatol2022;28:380-95 PMCID:PMC9293618

[29] Morris T,Hobbs A.Effects of low-dose aspirin on acute inflammatory responses in humans.J Immunol2009;183:2089-96

[30] Abdelmalak J,Con D.The effect of aspirin use on incident hepatocellular carcinoma - an updated systematic review and meta-analysis.Cancers2023;15:3518 PMCID:PMC10341252

[31] Wang S,Ryan PM.Association of aspirin therapy with risk of hepatocellular carcinoma: a systematic review and dose-response analysis of cohort studies with 2.5 million participants.Pharmacol Res2020;151:104585

[32] Lee CH,Yen TH,Yu MC.Daily aspirin reduced the incidence of hepatocellular carcinoma and overall mortality in patients with cirrhosis.Cancers2023;15:2946 PMCID:PMC10251874

[33] Liu Y,Xu X.Association of aspirin and nonaspirin NSAIDs therapy with the incidence risk of hepatocellular carcinoma: a systematic review and meta-analysis on cohort studies.Eur J Cancer Prev2022;31:35-43

[34] Memel ZN,Moninuola O.Aspirin use is associated with a reduced incidence of hepatocellular carcinoma: a systematic review and meta-analysis.Hepatol Commun2021;5:133-43 PMCID:PMC7789838

[35] Singh J,Cotler SJ.Combined use of aspirin and statin is associated with a decreased incidence of hepatocellular carcinoma.J Clin Gastroenterol2022;56:369-73

[36] Tan JL,Woodman R.Regular aspirin use is associated with a reduced risk of hepatocellular carcinoma (HCC) in chronic liver disease: a systematic review and meta-analysis.J Gastrointest Cancer2023;54:325-31

[37] Wang J.Impact of statin use on the risk and prognosis of hepatocellular carcinoma: a meta-analysis.Eur J Gastroenterol Hepatol2021;33:1603-9

[38] Zeng RW,Tan DJH.Meta-analysis: chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin.Aliment Pharmacol Ther2023;57:600-9 PMCID:PMC10792521

[39] Zhang S,Zhang B,Liu B.A systematic review of statins for the treatment of nonalcoholic steatohepatitis: safety, efficacy, and mechanism of action.Molecules2024;29:1859 PMCID:PMC11052408

[40] Sharpton SR.Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC.Hepatology2023;78:1896-906

[41] Cipollone F,Porreca E.Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy.Circulation2002;106:399-402

[42] Yano M,Senokuchi T.Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages.Circ Res2007;100:1442-51

[43] Zou B,Nguyen MH.Statin use and reduced hepatocellular carcinoma risk in patients with nonalcoholic fatty liver disease.Clin Gastroenterol Hepatol2023;21:435-44.e6

[44] Wang Y,Wang M,Jia X.A meta-analysis of statin use and risk of hepatocellular carcinoma.Can J Gastroenterol Hepatol2022;2022:5389044 PMCID:PMC8958112

[45] Sung FC,Muo CH,Tsai WC.Statins reduce hepatocellular carcinoma risk in patients with chronic kidney disease and end-stage renal disease: a 17-year longitudinal study.Cancers2022;14:825 PMCID:PMC8834435

[46] Matsushita Y,Kaburagi J.Pravastatin use and cancer risk: a meta-analysis of individual patient data from long-term prospective controlled trials in Japan.Pharmacoepidemiol Drug Saf2010;19:196-202

[47] Cholesterol Treatment Trialists’ (CTT) Collaboration; Emberson JR, Kearney PM, Blackwell L, et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One 2012;7:e29849. PMCID:PMC3261846

[48] Facciorusso A,Singh S.Statin use decreases the incidence of hepatocellular carcinoma: an updated meta-analysis.Cancers2020;12:874 PMCID:PMC7225931

[49] Pinyopornpanish K,Butler RS,McCullough A.Chemopreventive effect of statin on hepatocellular carcinoma in patients with nonalcoholic steatohepatitis cirrhosis.Am J Gastroenterol2021;116:2258-69

[50] Fujiwara N,Crouchet E.Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease.Sci Transl Med2022;14:eabo4474 PMCID:PMC9236162

[51] Azit NA,Voon Meng L,Mokhtar S.Risk factors of hepatocellular carcinoma in type 2 diabetes patients: a two-centre study in a developing country.PLoS One2021;16:e0260675 PMCID:PMC8659343

[52] Chang Y,Zhou Z.Can statin treatment reduce the risk of hepatocellular carcinoma? A systematic review and meta-analysis.Technol Cancer Res Treat2020;19:1533033820934881 PMCID:PMC7307281

[53] German MN,Pickhardt PJ,Said A.Statin use is protective against hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: a case-control study.J Clin Gastroenterol2020;54:733-40

[54] Hashemi Rafsanjani MR, Rahimi R, Heidari-Soureshjani S, Darvishi M, Adeli OA, Abbaszadeh S. Statin use and hepatocellular carcinoma risk: a comprehensive meta-analysis and systematic review. Recent Pat Anticancer Drug Discov 2024.

[55] Islam MM,Walther BA,Jack Li YC.Statin use and the risk of hepatocellular carcinoma: a meta-analysis of observational studies.Cancers2020;12:671 PMCID:PMC7139959

[56] Khazaaleh S,Alomari M.Statin use reduces the risk of hepatocellular carcinoma: an updated meta-analysis and systematic review.Cureus2022;14:e27032 PMCID:PMC9388192

[57] Vell MS,Krishnan A.Association of statin use with risk of liver disease, hepatocellular carcinoma, and liver-related mortality.JAMA Netw Open2023;6:e2320222 PMCID:PMC10293910

[58] Wong YJ,Ng GK,Teo EK.Efficacy and safety of statin for hepatocellular carcinoma prevention among chronic liver disease patients: a systematic review and meta-analysis.J Clin Gastroenterol2021;55:615-23

[59] Zhang J,Liu D,Tan Y.Statin can reduce the risk of hepatocellular carcinoma among patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis.Eur J Gastroenterol Hepatol2023;35:353-8

[60] Rasha F,Simon TG.Hepatocellular carcinoma chemoprevention with generic agents.Semin Liver Dis2022;42:501-13 PMCID:PMC10870259

[61] Garcia-Compean D,Gonzalez-Gonzalez JA.Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management.World J Gastroenterol2009;15:280-8 PMCID:PMC2653324

[62] Tangjarusritaratorn T,Kunavisarut T.Incidence and survival of hepatocellular carcinoma in type 2 diabetes patients with cirrhosis who were treated with and without metformin.Diabetes Metab Syndr Obes2021;14:1563-74 PMCID:PMC8043797

[63] Ribback S,Yasser M.Hepatocellular ballooning is due to highly pronounced glycogenosis potentially associated with steatosis and metabolic reprogramming.J Clin Transl Hepatol2024;12:52-61 PMCID:PMC10794273

[64] Li Q,Sui C.Impact of metformin use on risk and mortality of hepatocellular carcinoma in diabetes mellitus.Clin Res Hepatol Gastroenterol2022;46:101781

[65] Shankaraiah RC,Guerriero P.Metformin prevents liver tumourigenesis by attenuating fibrosis in a transgenic mouse model of hepatocellular carcinoma.Oncogene2019;38:7035-45

[66] Kramer JR,Dai J.Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease.Hepatology2022;75:1420-8 PMCID:PMC9107529

[67] Vilar-Gomez E,Wong VW.Type 2 diabetes and metformin use associate with outcomes of patients with nonalcoholic steatohepatitis-related, child-pugh a cirrhosis.Clin Gastroenterol Hepatol2021;19:136-45.e6

[68] Huynh DJ,Jamorabo DS.Reduced mortality and morbidity associated with metformin and SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and cirrhosis.BMC Gastroenterol2023;23:450 PMCID:PMC10731715

[69] Wang L,Kaelber DC.Association of GLP-1 Receptor agonists and hepatocellular carcinoma incidence and hepatic decompensation in patients with type 2 diabetes.Gastroenterology2024;167:689-703

[70] Elsaid MI,Firkins SA.Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes.Aliment Pharmacol Ther2024;59:1096-110

[71] Dwinata M,Hasan I.SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: a systematic review.Clin Exp Hepatol2020;6:339-46 PMCID:PMC7816633

[72] Bea S,Kim JH,Azoulay L.Sodium-glucose cotransporter-2 inhibitors and risk of hepatocellular carcinoma among patients with type 2 diabetes.Clin Gastroenterol Hepatol2023;21:3451-4.e4

[73] Cho HJ,Kim SS.SGLT2i impact on HCC incidence in patients with fatty liver disease and diabetes: a nation-wide cohort study in South Korea.Sci Rep2024;14:9761 PMCID:PMC11058854